| Document |
Document Title |
|
WO/2020/127385A1 |
A method is provided for preparing a compound d having the formula: Formula (I). The method comprises carrying out the following reaction: Formula (i), (ii), (d) where: step (i) is carried out in the presence of a metal catalyst and a hy...
|
|
WO/2020/018547A1 |
The present disclosure relates to methods for treating lupus nephritis with compositions comprising an effective amount of certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxam
ide compounds of Formula (I), including pharm...
|
|
WO/2020/018551A1 |
The present disclosure relates to methods for treating inflammatory bowel disease, with compositions comprising an effective amount of certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxam
ide compounds of Formula (I), inc...
|
|
WO/2018/213491A9 |
The present invention is directed to, in part, methods of preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. In so...
|
|
WO/2019/141229A1 |
The present invention involves compounds as PPAR agonists and applications thereof. The compounds involved are novel peroxisome proliferator-activated receptor (PPAR) γ receptor agonists and can inhibit the production of mitochondrial r...
|
|
WO/2019/082910A1 |
Provided are: a V2 receptor antagonist which has high water solubility and which is particularly suitable for injections; and a medicine containing the V2 receptor antagonist or the like. The present invention is a compound represented b...
|
|
WO/2018/235926A1 |
The purpose of the present invention is to provide an α, β-unsaturated amide compound or a pharmaceutically acceptable salt thereof or the like, which has anti-cancer activity or the like. An α, β-unsaturated amide compound represent...
|
|
WO/2018/193117A1 |
This invention relates to compounds that are useful as cancer therapies. The compounds comprise azithromycin derivatives having a phosphonium cation tethered to the azithromycin macrocycle. The invention also relates to methods of using ...
|
|
WO/2018/115421A1 |
The present invention discloses compounds of formula (I) that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).
|
|
WO/2018/104766A1 |
The present invention relates to compounds of Formula (I), and Formula (II), wherein B is benzotriazolyl, phenyl, triazolopyridinyl, or -(CH2)2-triazolyl each of which may be unsubstituted or substituted by 1, 2, or 3 substituents indepe...
|
|
WO/2018/022978A1 |
The present disclosure relates to methods for treating bronchiectasis, for example, non-cystic fibrosis bronchiectasis with compositions comprising an effective amount of certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carbox...
|
|
WO/2018/007973A2 |
Disclosed is a new process and intermediates for preparing benzoxazepines of Formula (I): (I) wherein Q is, and A, L, B, RA and m are as defined herein.
|
|
WO/2018/009417A1 |
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to macrocyclic α-keto amide derivatives and their use as therapeutic agents.
|
|
WO/2017/222083A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, X1, X2, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12and R13 are as defined in the specification, processes for their p...
|
|
WO/2017/215600A1 |
Provided are a substituted tricyclic herteocyclic compound of formula I or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, ester or a prodrug thereof, a pharmaceutical compo...
|
|
WO/2017/205536A2 |
The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compou...
|
|
WO/2017/132752A1 |
A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in...
|
|
WO/2017/098430A1 |
The present invention relates to a new chemical synthesis, intermediates and catalysts useful for the preparation of the neprilysin (NEP) inhibitor sacubitril. It further relates to new intermediate compounds and their use for said new c...
|
|
WO/2016/203401A1 |
The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.
|
|
WO/2016/198366A1 |
The instant invention relates to novel conjugates of formula (I): S - L - A (I) or salts thereof, wherein A is a gamma-secretase inhibitor, L is a linker and S is a peptidase-specific substrate, as well as processes for their manufacture...
|
|
WO/2015/123519A9 |
The present disclosure provides processes for the preparation of a compound of formula: which is a selective late sodium current inhibitor. The disclosure also provides compounds that are synthetic intermediates.
|
|
WO/2016/149581A1 |
Provided herein are compounds of formula (I) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
|
|
WO/2016/126725A1 |
The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I:, where R, L, X1, X2, X3, X4, Y1, Y2, Y...
|
|
WO/2016/126722A1 |
The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: (Formula I should be inserted here) wh...
|
|
WO/2016/126726A1 |
The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II: where R, L, X1, X2, X3,X4, X5, Y1, Y2, ...
|
|
WO/2016/126721A1 |
The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formula I:(Formula I should be inserted here), where R, L, X1, X2...
|
|
WO/2016/126724A1 |
The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I:(Formula I should be inserted here) whe...
|
|
WO/2016/087370A1 |
The present invention relates to derivatives of formula (I) wherein (R1)n, ring (A), Y1, Y2, X, R4, L1, L2, and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use...
|
|
WO/2016/075239A1 |
The invention relates to aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amide derivatives of general formula (l),which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders relat...
|
|
WO/2016/075240A1 |
The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addit...
|
|
WO/2016/055028A1 |
The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300....
|
|
WO/2016/019588A1 |
Compounds, compositions, and methods for treating C. difficile are provided.
|
|
WO/2016/012333A1 |
A method of combating and controlling insects, acarines, nematodes or molluscs which comprises applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest an insecticidally, acaricidally, nematicidally or moll...
|
|
WO/2015/138500A1 |
A genus of arylsulfonamide derivatives of aminocycloalkanols is disclosed. The compounds are of the following genus (I):. The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2A and, as a consequen...
|
|
WO/2015/110826A1 |
The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), (Formula (I)) that inhibit dipeptidyl peptidase 1(DPP1) activity,...
|
|
WO/2015/109130A1 |
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
|
|
WO/2015/056782A1 |
The purpose of the present invention is to provide a novel compound having ACC2-inhibiting activity and to provide a pharmaceutical composition comprising said compound. A compound indicated by formula (in the formula, R1 indicates a sub...
|
|
WO/2014/125444A1 |
Disclosed are compounds having the formula (I) wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.
|
|
WO/2014/057080A2 |
The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.
|
|
WO/2014/023708A1 |
There are provided compounds of the formula (1) wherein W, X, Y, Z, R1, R2, R3, R4, R5 and R6 are described herein. These compounds are useful for the treatment of proliferative diseases, including cancer.
|
|
WO/2013/119564A1 |
It has been determined that co-administration of a rifamycin and a switch-region inhibitor 1) results in synergistic antibacterial effects, enabling efficacy at low, subtoxic doses, and/or 2) results in a low spontaneous resistance frequ...
|
|
WO/2013/100158A1 |
An actinic ray-sensitive or radiation-sensitive resin composition, which is excellent in sensitivity, resolution, a pattern profile and a depth of focus (DOF), and, an actinic ray-sensitive or radiation-sensitive film and a pattern formi...
|
|
WO/2013/064231A1 |
The invention provides modulators for the orphan nuclear receptor RORγ and methods for treating RORγ mediated diseases by administration of these novel RORγ modulators to a human or a mammal in need thereof. Specifically, the present ...
|
|
WO/2013/033245A1 |
The oxidative functionalization of olefins is a common method for the formation of vicinal carbon-heteroatom bonds. However, oxidative methods to transform allenes into synthetic motifs containing three contiguous carbon-heteroatom bonds...
|
|
WO/2013/006463A1 |
The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the c...
|
|
WO/2013/006485A1 |
The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the c...
|
|
WO/2012/167171A2 |
The present invention relates generally to olefin metathesis. In some embodiments, the present invention provides methods for Z-selective ring-closing metathesis.
|
|
WO/2012/161622A2 |
The invention relates to the field of medicinal chemistry, pharmacology and medicine and contains a description of pharmaceutical compositions and combination drugs based on secretion stimulators and protectors of incretin hormones for t...
|
|
WO/2012/152915A1 |
The present invention relates to benzazepine derivatives of the formula (I) or a physiologically tolerated salt thereof. The present invention also relates to pharmaceutical compositions comprising such benzazepine derivatives, and the u...
|
|
WO/2012/126791A1 |
The present invention relates to 1,4-Oxazepines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active com...
|
